PART II – OTHER INFORMATION
Item 1. Legal Proceedings
On June 11, 2025 and July 18, 2025, two stockholders filed putative securities class action lawsuits against us and certain of our executive officers in the United States District Court for the District of New Jersey, purportedly on behalf of classes of the Company’s investors who purchased or otherwise acquired the Company’s common stock between February 27, 2025 and May 26, 2025 (Ho v. Rocket Pharmaceuticals, Inc., and Gaurav Shah, Case No. 3:25-cv-10049) and between September 17, 2024 and May 26, 2025 (Yankov v. Rocket Pharmaceuticals, Inc., Gaurav Shah and Aaron Ondrey, 3:25-cv-13532), respectively. The complaints alleged violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder in connection with various public statements made by the Company regarding its Phase 2 clinical trial for RP-A501 for Danon disease. The actions sought unspecified damages, costs and expenses, including attorneys’ fees. On September 9, 2025, the Court consolidated the two pending putative securities class action lawsuits, appointed two stockholders as co-lead plaintiffs, and approved their selection of co-lead counsel. Pursuant to a stipulation approved by the Court on September 22, 2025, the co-lead plaintiffs filed a consolidated amended complaint on November 18, 2025. The consolidated amended complaint, captioned In re Rocket Pharmaceuticals, Inc. Securities Litigation, 3:25-cv-10049, was brought on behalf of persons who purchased or otherwise acquired the Company’s securities during the period of February 28, 2024 through August 25, 2025 (inclusive). Plaintiffs claimed that the lawsuit arose from Defendants’ public statements and purported omissions concerning Rocket’s Phase 2 clinical trial for RP-A501 for DD. On October 28, 2026, the Court dismissed with prejudice the Plaintiffs’ claims that Rocket misled investors by failing to disclose serious adverse events in the Phase 2 trial and changes to the trial’s planning and design, including the addition of the C3 inhibitor. The Court dismissed without prejudice the remaining claim that the Company misrepresented the progress of patient dosing and the reasons for trial delays, as well as the related “control person” claims against D. Shah and Mr. Ondrey.
On October 22, 2025, a putative derivative action was filed in the District of New Jersey, naming as Defendants certain of the Company’s officers and present or former directors of the Company. The Complaint (which names the Company as a nominal defendant) alleges that the Defendants engaged in wrongful conduct during the period from September 17, 2024 through May 26, 2025. The allegations in the complaint largely parallel the allegations made in the previously filed putative securities class action complaints, with some additional allegations regarding a supposed lack of internal controls and purported insider trading. The Complaint seeks declaratory relief, an award of damages to the Company, an order directing the Company and the individual defendants to institute certain requested corporate governance reforms, restitution from the individual defendants, and costs and disbursements related to the lawsuit. The parties agreed to stay all proceedings in the putative derivative action until any motions to dismiss the putative securities class action are resolved, and on December 22, 2025, the Court approved the parties’ stipulation to that effect. The Company intends to vigorously defend the litigation. The Company will pay the legal fees related to the putative derivative action against the Company’s officers and directors. Given the nature of the litigation, including the fact that the litigation is in its early stages, the Company is unable to predict the ultimate outcome of the litigation or estimate the range of potential loss, if any.
From time to time, we may be subject to various legal proceedings and claims that arise in the ordinary course of our business activities. Although the results of litigation and claims cannot be predicted with certainty, we do not believe we are party to any other claim or litigation the outcome of which, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our business. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.
Item 1A. Risk Factors
Our material risk factors are disclosed in Item 1A of our 2025 Form 10-K. Other than the risk factors listed below, there have been no material changes from the risk factors previously disclosed in such filing.
The covenants in our Loan Agreement restrict our operating and financial flexibility, and a default could result in acceleration of our indebtedness, which may have an adverse effect on our business.
On September 30, 2026, we and certain of our subsidiaries entered into the Loan Agreement with Hercules, as administrative agent and collateral agent, and the lenders party thereto, providing for up to $150.0 million of senior secured Term Loans. Our obligations are secured by a first-priority security interest in substantially all of our assets, including intellectual property, subject to permitted liens and other exceptions.
The Loan Agreement contains affirmative and negative covenants that, subject to specified exceptions, restrict our ability to incur or prepay indebtedness, grant liens, make investments and acquisitions, sell or license assets, merge or consolidate, pay cash dividends or other distributions, repurchase equity interests and enter into affiliate transactions. These covenants could limit our ability to obtain additional financing, pursue collaborations or strategic transactions, or respond to business opportunities and adverse developments. Transactions outside the permitted exceptions may require lender consent, which may not be forthcoming.